First Tracks Q2: FDA Fast Track for ANB033, Cash Runway Extended to Q2 2028

summarizeSummary

First Tracks Biotherapeutics reported Q2 2026 results with a $33.4M net loss and $168.0M cash, while announcing FDA Fast Track designation for ANB033 in celiac disease and extending cash runway into Q2 2028.

check_boxKey Events · Earnings and Guidance · TRAX

• FDA Fast Track for ANB033

  The FDA granted Fast Track designation to ANB033 for the treatment of celiac disease, underscoring the unmet need and potential of the program.

• Cash Runway Extended to Q2 2028

  Cash, cash equivalents and investments totaled $168.0 million as of June 30, 2026, extending the runway into Q2 2028, including expansion into two additional indications in H1 2027.

• Cohort 2 Enhanced in Celiac Trial

  Cohort 2 of the Phase 1b ANB033 trial in celiac disease was enhanced to enroll up to 40 patients with a broad range of histologic (Vh:Cd ratio ≤ 2.5) and symptom severity, with top-line data anticipated in Q1 2027.

• Q2 2026 Financial Results

  Net loss was $33.4 million for Q2 2026, or $0.95 per share, compared to a net loss of $42.4 million, or $1.47 per share, in Q2 2025. R&D expenses decreased to $25.6 million from $39.3 million.

auto_awesomeAnalysis · TRAX · Life Sciences

First Tracks reported Q2 2026 results with a net loss of $33.4 million and cash of $168.0 million, but the real news is the FDA granting Fast Track designation to ANB033 for celiac disease and the extension of cash runway into Q2 2028. The company also enhanced Cohort 2 of its Phase 1b celiac trial to enroll up to 40 patients with broader disease severity, and plans to initiate Phase 2 trials in two additional indications in H1 2027. These updates strengthen the clinical and financial outlook for a company that recently spun off from AnaptysBio.